Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients
PharmD, MPH, MBA Essy Mozaffari, PhD Aastha Chandak, MD, PhD Andrew Ustianowski, PharmD, RPh Christina G Rivera, MD, FACP Neera Ahuja, MPH Heng Jiang, PhD Mark Berry, MD Jason F Okulicz, MD Alpesh N Amin
Clinical Therapeutics, doi:10.1016/j.clinthera.2024.08.004
Implications: A significant proportion of patients hospitalized for COVID-19 receive medications for other conditions that have the potential to result in DDIs with DAAs; most predominantly with nirmatrelvir/ritonavir, a strong CYP3A enzyme inhibitor, fewer with remdesivir, and none with molnupiravir. Higher age and comorbidity burden were significantly associated with a higher likelihood of receiving medications that are "Contraindicated " with nirmatrelvir/ritonavir. In the evolving COVID-19 era, these findings provide insights into patients hospitalized for COVID-19, and the polypharmacy evaluations that clinicians may encounter when selecting among DAAs to manage COVID-19.
Declaration of competing interest Summary of ICMJE forms: Essy Mozaffari is an employee of Gilead Sciences, Inc. and holds stock or stock options. Aastha Chandak is an employee of Certara and declares support provided by Gilead Sciences, Inc. to her institution. Andrew Ustianowski declares consulting fees provided by Generate Biomedicines, Gilead Sciences, Inc., Merck/MSD, and Pfizer Inc. and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events, and/or participation on a Data Safety Monitoring Board or Advisory Board from Astra Zeneca, Gilead Sciences, Inc., and GSK. Christina G. Rivera declares the receipt of grant or contracts from Gilead Science, Inc. as payment to PI colleague, consulting fees and participation on a Data Safety Monitoring Board or Advisory Board from Gilead Science, Inc., and payment of honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Jobson Health, Continuing Education Network, CE Impact, Insmed, Gilead Sciences, Inc., Annenberg Center for Health Science, American College of Clinical Pharmacy, and PharmCon Healthcare Education. Neera Ahuja declares payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Gilead Sciences, Inc. Heng Jiang is an employee of Certara and declares support provided by Gilead Sciences, Inc. to his institution. Mark Berry is an employee of Gilead Sciences, Inc...
References
Abraham, Nohria, Neilan, Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19: JACC review topic of the week, J Am Coll Cardiol
Bigdelou, Sepand, Najafikhoshnoo, COVID-19 and preexisting comorbidities: risks, synergies, and clinical outcomes, Front Immunol
Carpenter, Berry, Pelletier, Clinically relevant drug-drug interactions in primary care, Am Fam Physician
Chan, Current and future direct-acting antivirals against COVID-19, Front Microbiol
Chang, Shariff, Bakar, Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals, J Pharm Policy Pract
Day, Snowden, Mclachlan, Life-threatening drug interactions: what the physician needs to know, Intern Med J
Ghasemi, Darvishi, Salari, Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies, Trop Med Health
Iloanusi, Mgbere, Essien, Polypharmacy among COVID-19 patients: a systematic review, J Am Pharm Assoc
Kumar, Trivedi, Disease-drug and drug-drug interaction in COVID-19: risk and assessment, Biomed Pharmacother
Larsen, Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19, Int J Infect Dis
Lemaitre, Grégoire, Monchaud, Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for COVID-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT), Therapie
Marzolini, Kuritzkes, Marra, Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlodid) and comedications, Clin Pharmacol Ther
Russell, Lone, Baillie, Comorbidities, multimorbidity and COVID-19, ARTICLE IN PRESS JID: CLITHE [m5GeSdc
Singh, De, Antiviral agents for the treatment of COVID-19: progress and challenges, Cell Rep Med
Sirois, Boiteau, Chiu, Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada, BMJ Open
Who, COVID-19: WHO health emergency appeal
{ 'indexed': {'date-parts': [[2024, 9, 8]], 'date-time': '2024-09-08T00:26:02Z', 'timestamp': 1725755162978},
'reference-count': 24,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2024, 9, 1]],
'date-time': '2024-09-01T00:00:00Z',
'timestamp': 1725148800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2024, 9, 1]],
'date-time': '2024-09-01T00:00:00Z',
'timestamp': 1725148800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/legal/tdmrep-license'},
{ 'start': { 'date-parts': [[2024, 8, 20]],
'date-time': '2024-08-20T00:00:00Z',
'timestamp': 1724112000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'funder': [ { 'DOI': '10.13039/100005564',
'name': 'Gilead Sciences Inc',
'doi-asserted-by': 'publisher',
'id': [{'id': '10.13039/100005564', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicaltherapeutics.com',
'clinicalkey.com.au', 'clinicalkey.es', 'clinicalkey.com', 'elsevier.com',
'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 9]]},
'DOI': '10.1016/j.clinthera.2024.08.004',
'type': 'journal-article',
'created': {'date-parts': [[2024, 9, 7]], 'date-time': '2024-09-07T10:29:38Z', 'timestamp': 1725704978000},
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among '
'Hospitalized Patients',
'prefix': '10.1016',
'author': [ {'given': 'Essy', 'family': 'Mozaffari', 'sequence': 'first', 'affiliation': []},
{'given': 'Aastha', 'family': 'Chandak', 'sequence': 'additional', 'affiliation': []},
{'given': 'Andrew', 'family': 'Ustianowski', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-8308-3264',
'authenticated-orcid': False,
'given': 'Christina G.',
'family': 'Rivera',
'sequence': 'additional',
'affiliation': []},
{'given': 'Neera', 'family': 'Ahuja', 'sequence': 'additional', 'affiliation': []},
{'given': 'Heng', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mark', 'family': 'Berry', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jason F.', 'family': 'Okulicz', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alpesh N.', 'family': 'Amin', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.clinthera.2024.08.004_bib0001',
'unstructured': 'CDC. COVID data tracker. 2024. '
'https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions. '
'Accessed March 15, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0002',
'unstructured': 'WHO. COVID-19: WHO health emergency appeal. 2024. '
'https://www.who.int/publications/m/item/covid-19-who-health-emergency-appeal-2024. '
'Accessed January 16, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0003',
'unstructured': 'CDC. Underlying medical conditions associated with higher risk for '
'severe COVID-19: information for healthcare professionals. 2023. '
'https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. '
'Accessed February 6, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0004',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fimmu.2022.890517',
'article-title': 'COVID-19 and preexisting comorbidities: risks, synergies, and clinical '
'outcomes',
'volume': '13',
'author': 'Bigdelou',
'year': '2022',
'journal-title': 'Front Immunol'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0005',
'doi-asserted-by': 'crossref',
'first-page': '334',
'DOI': '10.1038/s41591-022-02156-9',
'article-title': 'Comorbidities, multimorbidity and COVID-19',
'volume': '29',
'author': 'Russell',
'year': '2023',
'journal-title': 'Nat Med'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0006',
'doi-asserted-by': 'crossref',
'first-page': '2',
'DOI': '10.1186/s40545-022-00504-1',
'article-title': 'Polypharmacy and potentially inappropriate medications among '
'hospitalized older adults with COVID-19 in Malaysian tertiary hospitals',
'volume': '16',
'author': 'Chang',
'year': '2023',
'journal-title': 'J Pharm Policy Pract'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0007',
'doi-asserted-by': 'crossref',
'first-page': '60',
'DOI': '10.1186/s41182-022-00456-x',
'article-title': 'Global prevalence of polypharmacy among the COVID-19 patients: a '
'comprehensive systematic review and meta-analysis of observational '
'studies',
'volume': '50',
'author': 'Ghasemi',
'year': '2022',
'journal-title': 'Trop Med Health'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0008',
'doi-asserted-by': 'crossref',
'first-page': 'e14',
'DOI': '10.1016/j.japh.2021.05.006',
'article-title': 'Polypharmacy among COVID-19 patients: a systematic review',
'volume': '61',
'author': 'Iloanusi',
'year': '2021',
'journal-title': 'J Am Pharm Assoc (2003)'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0009',
'doi-asserted-by': 'crossref',
'DOI': '10.1136/bmjopen-2021-060295',
'article-title': 'Exploring the associations between polypharmacy and COVID-19-related '
'hospitalisations and deaths: a population-based cohort study among '
'older adults in Quebec, Canada',
'volume': '12',
'author': 'Sirois',
'year': '2022',
'journal-title': 'BMJ Open'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0010',
'article-title': 'Antiviral agents for the treatment of COVID-19: progress and challenges',
'volume': '3',
'author': 'Singh',
'year': '2022',
'journal-title': 'Cell Rep Med'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0011',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fmicb.2020.587944',
'article-title': 'Current and future direct-acting antivirals against COVID-19',
'volume': '11',
'author': 'Chan',
'year': '2020',
'journal-title': 'Front Microbiol'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0012',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.biopha.2021.111642',
'article-title': 'Disease-drug and drug-drug interaction in COVID-19: risk and assessment',
'volume': '139',
'author': 'Kumar',
'year': '2021',
'journal-title': 'Biomed Pharmacother'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0013',
'doi-asserted-by': 'crossref',
'first-page': '1191',
'DOI': '10.1002/cpt.2646',
'article-title': 'Recommendations for the management of drug-drug interactions between '
'the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlodid) and '
'comedications',
'volume': '112',
'author': 'Marzolini',
'year': '2022',
'journal-title': 'Clin Pharmacol Ther'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0014',
'unstructured': 'FDA. Fact sheet for healthcare providers: emergency use authorization '
'for Paxlovid. 2024. https://www.fda.gov/media/155050/download. Accessed '
'February 10, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0015',
'unstructured': 'FDA. Remdesivir prescribing information. 2020. '
'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf. '
'Accessed February 10, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0016',
'unstructured': 'FDA. Fact sheet for healthcare providers: emergency use authorization '
'for Lagevrio. 2023. https://www.fda.gov/media/155054/download. Accessed '
'February 10, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0017',
'unstructured': 'FDA. Antimicrobial Drugs Advisory Committee Meeting (16 March 2023). '
'2023. https://www.fda.gov/media/166237/download. Accessed February 10, '
'2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0018',
'doi-asserted-by': 'crossref',
'first-page': '599',
'DOI': '10.1016/j.ijid.2022.06.059',
'article-title': 'Assessing the proportion of the Danish population at risk of clinically '
'significant drug-drug interactions with new oral antivirals for early '
'treatment of COVID-19',
'volume': '122',
'author': 'Larsen',
'year': '2022',
'journal-title': 'Int J Infect Dis'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0019',
'doi-asserted-by': 'crossref',
'first-page': '509',
'DOI': '10.1016/j.therap.2022.03.005',
'article-title': 'Management of drug-drug interactions with nirmatrelvir/ritonavir in '
'patients treated for COVID-19: guidelines from the French Society of '
'Pharmacology and Therapeutics (SFPT)',
'volume': '77',
'author': 'Lemaitre',
'year': '2022',
'journal-title': 'Therapie'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0020',
'unstructured': 'FDA. Paxlovid prescribing information. 2023. '
'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf. '
'Accessed March 7, 2024.'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0021',
'doi-asserted-by': 'crossref',
'first-page': '1912',
'DOI': '10.1016/j.jacc.2022.08.800',
'article-title': 'Cardiovascular drug interactions with nirmatrelvir/ritonavir in '
'patients with COVID-19: JACC review topic of the week',
'volume': '80',
'author': 'Abraham',
'year': '2022',
'journal-title': 'J Am Coll Cardiol'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0022',
'first-page': '558',
'article-title': 'Clinically relevant drug-drug interactions in primary care',
'volume': '99',
'author': 'Carpenter',
'year': '2019',
'journal-title': 'Am Fam Physician'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0023',
'doi-asserted-by': 'crossref',
'first-page': '501',
'DOI': '10.1111/imj.13404',
'article-title': 'Life-threatening drug interactions: what the physician needs to know',
'volume': '47',
'author': 'Day',
'year': '2017',
'journal-title': 'Intern Med J'},
{ 'key': '10.1016/j.clinthera.2024.08.004_bib0024',
'unstructured': 'NIH. Drug-drug interactions between ritonavir-boosted nirmatrelvir '
'(Paxlovid) and concomitant medications. 2024. '
'https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir–paxlovid-/paxlovid-drug-drug-interactions/. '
'Accessed February 12, 2024.'}],
'container-title': 'Clinical Therapeutics',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0149291824002157?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0149291824002157?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2024, 9, 7]],
'date-time': '2024-09-07T10:29:59Z',
'timestamp': 1725704999000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0149291824002157'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 9]]},
'references-count': 24,
'alternative-id': ['S0149291824002157'],
'URL': 'http://dx.doi.org/10.1016/j.clinthera.2024.08.004',
'relation': {},
'ISSN': ['0149-2918'],
'subject': [],
'container-title-short': 'Clinical Therapeutics',
'published': {'date-parts': [[2024, 9]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for '
'COVID-19 Among Hospitalized Patients',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'Clinical Therapeutics', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.clinthera.2024.08.004',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2024 The Authors. Published by Elsevier Inc.',
'name': 'copyright',
'label': 'Copyright'}]}
